

CorNeat KPro

Enabling Corneally Blind Patients to Fully Enjoy Their Vision Potential

Sponsored By:











Enabling Corneally Blind Patients to Fully Enjoy Their Vision Potential





Visual acuity

Deterministic, Wide field of view. Enables cataract surgery post operation



Healing & Retention

Device integrates to the eye wall using nano-fabric. Fast to heal and scar. Short post-operative follow up



Scalability

Relatively simple, 45 minute operation, Affordable price, No need for tissue

Novel Surgical Procedure

- Easy to teach
- Does not require "optical"

tissue alignment

Implantation Tools






Clinical end points: Safety, Retention, Sight Restoration

CorNeat KPro Trial - Implantations Vision: Displace the use of donor tissue globally • Phase I (Current) - Secondary indications: Failed grafts / Indications not suitable for transplantation / countries lacking donor tissue / aesthetics • Phase II: Primary penetrating keratoplasty (PKP) indications Today 2026 2022 2024 2023 2025 2027 2028 2029 2030 KPro First-In Human 10 Patients, 1 year FU 1yr FU 25 OUS Patients, 8 Sites 510K Clearance KPro Secondary (510K) +15 (US) CE Mark **Indications** 50-60 Patients, 3 Sites (China) NMPA Clearance Prep (China KPro Expanded (PKP) FDA (Denovo/PMA) Prep ~200 Patients, 2yr FU **Indications**



Regaining sight following over a decade of blindness





6/4.8 (20/16) Vision



Solution: Synthetic, Tissue-Integrating Implants that are simple to implant

- Long-lasting, superior functionality (optical performance, pressure regulation, tissue reinforcement)
- Novel tissue-integrating technology neutralizes foreign body response, improving anatomical and functional success

